California Neurology Society (CNS) Advocacy

The California Neurology Society’s Advocacy Day on Monday, April 13th brought neurologists, trainees, and advocates together at the State Capitol to elevate the voice of neurology in statewide policy discussions. The day was grounded in collaboration and purpose, giving clinicians the opportunity to share firsthand perspectives on patient care, workforce challenges, access barriers, and the realities facing neurology practices across California. By meeting directly with legislators and staff, participants helped ensure that the needs of people living with neurological conditions were clearly understood by those shaping health policy.

The gathering also strengthened the neurology community itself. Advocacy Day created space for colleagues from across the state to connect, exchange insights, and align around shared priorities. Whether discussing reimbursement issues, public health initiatives, or the future of neurological care delivery, the conversations throughout the day reinforced a collective commitment to improving outcomes for patients and supporting the clinicians who care for them.

As everyone came together in Sacramento, the energy was both hopeful and determined. Advocacy Day was not just a series of meetings—it served as a reminder of the impact neurologists can have when they speak with a unified voice. It offered an opportunity to highlight the importance of neurology in California’s healthcare landscape and to help shape policies that will influence care for years to come.

To express your interest in participating in future advocacy days or to get involved with the CNS Legislative Committee, please contact us directly at LEDGE@caneurologysociety.org.

The California Neurology Society is supporting a statewide prospective registry to advance understanding of Multiple Sclerosis (MS) and related autoimmune neurological diseases. Led by Principal Investigator Dr. Johanna Rosenthal, this collaborative effort brings together neurologists from Arrowhead Regional Medical Center, Riverside Community Hospital, and across California.

This registry collects de‑identified laboratory and clinical data—including immunoglobulin subclasses, lymphocyte populations, and flow cytometry results—to evaluate how modern Disease Modifying Therapies (DMTs) affect the immune system.

Participating neurologists submit data from consenting adult patients, with testing performed at standardized intervals before and after treatment.

By freezing and analyzing data quarterly, the registry aims to provide clinicians with meaningful insights into treatment response, support evidence‑based use of high‑cost therapies, and create a long‑term resource for research. The project includes an initial one‑year cohort of 100 patients, with potential for expansion based on findings.